U.S. markets close in 2 hours 7 minutes

BridgeBio Pharma, Inc. (BBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
48.79-0.80 (-1.61%)
As of 1:53PM EDT. Market open.

BridgeBio Pharma, Inc.

421 Kipling Street
Palo Alto, CA 94301
United States
650 391 9740
http://www.bridgebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees385

Key Executives

NameTitlePayExercisedYear Born
Dr. Neil KumarCo-Founder, CEO & Director897.57kN/A1980
Dr. Charles J. HomcyChairman of Pharmaceuticals & Lead Director735.54kN/A1948
Dr. Richard H. SchellerChairman of R&D and DirectorN/AN/A1953
Dr. Brian C. Stephenson C.F.A., Ph.D.CFO, Sec. & Principal Accounting OfficerN/AN/A1981
Ms. Yi Ching YauChief Accounting OfficerN/AN/AN/A
Dr. Uma SinhaChief Scientific OfficerN/AN/A1958
Dr. Frank McCormick Ph.D.Chairman of OncologyN/AN/A1950
Dr. Michael Thomas Henderson M.D.Chief Bus. OfficerN/AN/A1990
Dr. Cameron Turtle DPHIL, Ph.D.Chief Strategy OfficerN/AN/A1990
Mr. Eli M. WallaceChief Scientific Officer of Residence - Oncology ProgramsN/AN/A1967
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); and the University of California, Davis. The company was founded in 2015 and is headquartered in Palo Alto, California.

Corporate Governance

BridgeBio Pharma, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.